SPARTAN Trial Interim Results in Patients With IgAN | Docwire News
Researchers at SCM25 presented interim results of the SPARTAN trial of sparsentan as a treatment for patients with IgA nephropathy (IgAN).
Researchers at SCM25 presented interim results of the SPARTAN trial of sparsentan as a treatment for patients with IgA nephropathy (IgAN).
*Please mention the European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14) if using this research* Three months of time-restricted eating (TRE), irrespective of…
Researchers define characteristics of e-GISTS and determine whether endoscopic resection is a treatment option for patients.
We are thrilled to have Dr. Joel Kahn as our special guest. Dr. Kahn is an esteemed American cardiologist, integrative medicine practitioner, and a passionat…
Naval G. Daver, MD discusses the latest advancements in the treatment of myelodysplastic syndromes, with a focus on improving outcomes for patients with lower-risk disease.
The panel discusses a wave of bladder cancer therapies, including cretostimogene, gem/doce, and AI-driven biomarkers.
Axillary management, the evaluation and treatment of potentially cancerous lymph nodes in the underarm, is a key part of surgical planning for triple-negative breast cancer.
Dr. Spira explained that it was critical to evaluate the treatment in patients with atypical EGFR mutations because these patients usually don’t fare as well…
Axillary management, the evaluation and treatment of potentially cancerous lymph nodes in the underarm, is a key part of surgical planning for triple-negative breast cancer.
Edición especial en castellano con Alfonso Gómez de Liaño y Guillermo de Velasco. David Lorente da su visión sobre el nuevo Uromigos Score, que clasifica…